 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Experienced management with successful track-record
Innovative pipeline in large potential markets built on cutting-edge research:
- Lead product successfully completed Phase l/lla clinical trial in multiple sclerosis (MS) patients
- MS diagnostic blood test under development
- Therapeutic vaccine to prevent factor VIII inhibitor antibodies in haemophilia A patients under evaluation in pre clinical models
Patented, platform technology for identification of additional peptide-based
apitope
vaccines and diagnostics
Commercial agreements with global pharmaceutical companies
An exciting rapidly growing company with: